Illumina appeals FTC order to divest cancer test maker Grail
By Diane Bartz and Mrinmay Dey WASHINGTON (Reuters) -Illumina on Monday filed an appeal against a Federal Trade Commission (FTC) order, demanding that it divest cancer diagnostic test maker Grail over competition concerns in the U.S. market for cancer tests. San Diego-based Illumina is arguing that the FTC “violated due process by depriving Illumina and…